Results of Study Led by Renowned Swiss Research Team Cites
PCT as a Key Component in the Identification of New Protein
Biomarker Candidates for More Precise Classification of
Prostate Cancer
South Easton, MA -- June 29, 2015 -- InvestorsHub NewsWire
-- Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI and the
Company), a leader in the development and sale of broadly enabling,
pressure cycling technology (PCT)-based sample preparation
solutions to the worldwide life sciences industry, today announced
that Tiannan Guo, MD Ph.D. of the Institute of Molecular Systems
Biology, ETH Zurich, presented data on an improved method for the
proteomic profiling and classification of prostate cancer tissue
biopsy samples at the recent annual conference of the American
Society for Mass Spectrometry.
Dr. Guo and colleagues combined the Companys enhanced Barocycler
NEP2320 instrument and MicroPestle consumable (PCT-HD) with AB
Sciexs SWATH-MS mass spectrometric system (together, PCT-SWATH) to
permit what they characterize as the high throughput, reproducible,
quantitative profiling of proteins in biopsy tissues. The authors
concluded that PCT-SWATH (i) separated previously
histologically-indistinguishable tissue biopsy samples, and (ii)
identified new protein biomarker candidates for more precise
classification of prostate cancer. The authors indicated their
results await further validation in independent studies.
Dr. Nate Lawrence, Vice President of Marketing and Sales for
PBI, said: Patients with prostate cancer are generally classified
into three groups based on histological results: low-grade,
intermediate-grade, and high-grade. Patients in the
intermediate-grade group most often have mixed clinical outcomes.
Consequently, prostate cancer patients in this group need to be
better profiled and differentiated. This should enable more precise
classification, which should then lead to better prognosis and
treatment. Unfortunately, the authors believe that better
classification is not achievable with established diagnostic
procedures.
Dr. Lawrence continued: Using PCT-SWATH, the investigators
obtained a level of reproducibility and quantitative accuracy
comparable to SRM, the gold standard quantitative mass
spectrometric method. However, unlike SRM, which often results in
the maximal quantification of a few hundred proteins per sample,
PCT-SWATH resulted in the quantification of thousands of proteins,
with unprecedented speed and precision, thus offering the potential
for better classification of prostate cancer patients.
Mr. Richard T. Schumacher, President and CEO of PBI, stated:
According to the American Cancer Society (ACS), prostate cancer is
the second most common cancer and the second leading cause of
cancer death in American men. In 2015, the ACS estimates there will
be approximately 220,800 new cases of prostate cancer, with about
27,540 deaths. Current statistics indicate that about one man in
thirty-eight will die of prostate cancer. Consequently, laboratory
tools that can better diagnose and correctly classify the grade of
prostate cancer are vitally needed. We are pleased that one of the
top Key Opinion Leader laboratories in the world has adopted PCT as
a routine method for mass spectrometry sample preparation. We are
further pleased that they believe PCT-SWATH offers the potential
for wide applications in personalized medicine and that this method
may ultimately achieve adoption in the clinical laboratory
setting.
About PCT-HD and PCT-SWATH
The PCT-HD System combines two of the Companys unique products:
the recently released, patent-pending MicroPestle consumable with
an enhanced Barocycler NEP2320 instrument. This combination enables
faster, less cumbersome and higher quality homogenization,
extraction, and digestion of proteins. PCT-HD was developed by the
Companys scientists and engineers in collaboration with Professor
Ruedi Aebersold and Dr. Tiannan Guo of the Institute of Molecular
Systems Biology, ETH Zurich, and the University of Zurich, both in
Zurich, Switzerland. Drs. Aebersold and Guo have recently combined
PCT-HD with AB Sciexs SWATH-Mass Spectrometry calling the resulting
method PCT-SWATH.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) (OTCQB: PBIO) develops,
markets, and sells proprietary laboratory instrumentation and
associated consumables to the estimated $6 billion life sciences
sample preparation market. Our products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or PCT) hydrostatic pressure. PCT is a
patented enabling technology platform that uses alternating cycles
of hydrostatic pressure between ambient and ultra-high levels to
safely and reproducibly control bio-molecular interactions. To
date, we have installed over 250 PCT systems in approximately 160
sites worldwide. There are over 100 publications citing the
advantages of the PCT platform over competitive methods, many from
key opinion leaders. Our primary application development and sales
efforts are in the biomarker discovery and forensics areas.
Customers also use our products in other areas, such as drug
discovery & design, bio-therapeutics characterization, soil
& plant biology, vaccine development, histology, and forensic
applications.
Forward Looking Statements
Statements contained in this press release regarding PBI's
intentions, hopes, beliefs, expectations, or predictions of the
future are "forward-looking'' statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
are based upon the Company's current expectations, forecasts, and
assumptions that are subject to risks, uncertainties, and other
factors that could cause actual outcomes and results to differ
materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors include,
but are not limited to, the risks and uncertainties discussed under
the heading "Risk Factors" in the Company's Annual Report on Form
10-K for the year ended December 31, 2014, and other reports filed
by the Company from time to time with the SEC. The Company
undertakes no obligation to update any of the information included
in this release, except as otherwise required by law.
For more information about PBI and this press release, please
click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter
Richard T. Schumacher, President & CEO Pressure BioSciences,
Inc.
Nathan P. Lawrence, Ph.D. VP of Marketing and Sales (508)
230-1828 (T)